Analgin (Tablets, Capsules, Solution) Instructions for Use

Instructions
Dosage forms

ATC Code

N02BB02 (Metamizole sodium)

Active Substance

Metamizole sodium (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Analgesic-antipyretic

Pharmacotherapeutic Group

Analgesics; other analgesics and antipyretics; pyrazolones

Pharmacological Action

Analgesic-antipyretic, a pyrazolone derivative. It has analgesic, antipyretic, and anti-inflammatory effects, the mechanism of which is associated with the inhibition of prostaglandin synthesis.

Pharmacokinetics

After oral administration, Metamizole sodium is rapidly hydrolyzed in gastric juice to form the active metabolite 4-methyl-amino-antipyrine, which after absorption is metabolized to 4-formyl-amino-antipyrine and other metabolites.

After IV administration, Metamizole sodium rapidly becomes undetectable.

Sodium metamizole metabolites do not bind to plasma proteins. The largest part of the dose is excreted in the urine in the form of metabolites. Metabolites are excreted in breast milk.

Indications

Pain syndrome of various origins (renal and biliary colic, neuralgia, myalgia; in trauma, burns, after surgery; headache, toothache, menstrual pain). Fever in infectious and inflammatory diseases.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
K08.8	Other specified disorders of teeth and supporting structures (including toothache)
K80	Cholelithiasis [cholelithiasis] (including biliary colic)
M79.1	Myalgia
M79.2	Neuralgia and neuritis, unspecified
N23	Unspecified renal colic
N94.4	Primary dysmenorrhea
N94.5	Secondary dysmenorrhea
R50	Fever of unknown origin
R51	Headache
R52.0	Acute pain
R52.2	Other chronic pain
T14.3	Dislocation, sprain and strain of joint and ligament of unspecified body region
T30	Burns and corrosions of unspecified body region

ICD-11 code	Indication
8A8Z	Headache disorders, unspecified
8E4A.1	Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
DA0A.Z	Diseases of teeth and supporting structures, unspecified
DC11.Z	Cholelithiasis, unspecified
FB56	Specified soft tissue diseases, not elsewhere classified
FB56.2	Myalgia
GA34.3	Dysmenorrhea
LA30.5Z	Anomalies of tooth resorption or loss, unspecified
MF56	Renal colic
MG26	Fever of other or unknown origin
MG30.Z	Chronic pain syndrome, unspecified
MG31.Z	Acute pain, unspecified
ND56.3	Dislocation, sprain or strain of unspecified body region
NE11	Burn of unspecified body region

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets, Capsules, Solution

Administered orally, IM and IV slowly. The dose, method and scheme of application, duration of application are determined individually, depending on the indications, clinical situation, dosage form and age of the patient.

For oral administration, a single dose for adults and adolescents over 15 years of age is 250-500 mg. The maximum single dose is 1000 mg. Frequency of administration – 2-3 times/day. The maximum daily dose is 2000 mg.

For IM or IV administration, a single dose for adults and adolescents over 15 years of age is 500-1000 mg. The maximum single dose is 1000 mg. The maximum daily dose is 2000 mg, frequency of administration 2-3 times/day.

For children aged 3-12 months (body weight 5-9 kg), Metamizole sodium is administered only IM at a dose of 50-100 mg per 10 kg of body weight; frequency – 2-3 times/day.

The duration of application is 1-5 days when prescribed as an analgesic and 1-3 days as an antipyretic.

Adverse Reactions

From the cardiovascular system infrequently – isolated arterial hypotension. After taking sodium metamizole, an isolated transient decrease in blood pressure is possible (possibly pharmacologically determined and not accompanied by other manifestations of anaphylactic/anaphylactoid reactions); in rare cases, the decrease in blood pressure can be very sharp; in fever, a dose-dependent sharp decrease in blood pressure without other signs of a hypersensitivity reaction is also possible; frequency unknown – Kounis syndrome (allergic coronary syndrome, manifested by clinical and laboratory signs of angina pectoris caused by inflammatory mediators).

From the immune system rarely – anaphylactic/anaphylactoid reactions; very rarely – analgesic bronchial asthma; frequency unknown – anaphylactic shock. Anaphylactic or anaphylactoid reactions in very rare cases can be severe and life-threatening. They can occur even if the patient has taken Metamizole sodium many times before without any complications. Such reactions can develop immediately or several hours after taking sodium metamizole, usually within 1 hour. In milder cases, they manifest as skin and mucosal symptoms (itching, burning, redness, urticaria, swelling) or as shortness of breath or gastrointestinal complaints. In severe cases, these reactions progress to generalized urticaria, severe angioedema (especially involving the larynx), severe bronchospasm, cardiac arrhythmia, sharp decrease in blood pressure (sometimes preceded by an increase in blood pressure) and the development of circulatory shock. In persons with analgesic bronchial asthma syndrome with intolerance to analgesic drugs, these reactions usually manifest as attacks of bronchial asthma.

From the skin and subcutaneous tissues infrequently – fixed drug dermatitis; rarely – skin rash; frequency unknown – Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome).

From the hematopoietic and lymphatic system rarely – leukopenia; very rarely – agranulocytosis, including fatal cases and thrombocytopenia; frequency unknown – aplastic anemia, pancytopenia, including fatal cases. These reactions are immunological in nature. They can occur even if the patient has taken Metamizole sodium many times without any complications. Typical symptoms of agranulocytosis are lesions of the mucous membranes (oral cavity and pharynx, anorectal area and genitals), sore throat, fever. However, with the use of antibiotics, these phenomena may be mild. Sometimes, but not always, there is a slight enlargement of the lymph nodes or spleen. ESR is significantly increased, the granulocyte count is sharply reduced or undetectable. As a rule, hemoglobin, erythrocyte and platelet levels remain normal, but deviations are possible. Typical symptoms of thrombocytopenia are increased bleeding tendency and the appearance of petechiae on the skin and mucous membranes. If there is an unexpected deterioration in general condition, fever does not subside or new or painful ulcerations appear on the mucous membranes, especially in the mouth, nose or throat, the treatment strategy involves immediate discontinuation of sodium metamizole, without waiting for the results of laboratory tests. If pancytopenia develops, Metamizole sodium should be discontinued and a complete blood count should be monitored until its parameters return to normal.

From the urinary system: very rarely – in patients with impaired renal function, acute deterioration of renal function (acute renal failure) is possible, in some cases with oliguria, anuria or proteinuria.

General reactions infrequently – possible red coloration of urine due to the presence of the metabolite – rubazonic acid; very rarely – phlebitis.

Local reactions with IM administration – infiltrates at the injection site.

Contraindications

Hypersensitivity to sodium metamizole and other pyrazolone derivatives, as well as to pyrazolidines, for example, phenylbutazone (including patients who have had agranulocytosis due to the use of these drugs); analgesic bronchial asthma or analgesic intolerance (of the urticaria-angioedema type), i.e. patients with bronchospasm or other forms of anaphylactoid reactions (e.g., urticaria, rhinitis, angioedema) in response to the use of salicylates, paracetamol or NSAIDs such as diclofenac, ibuprofen, indomethacin or naproxen; impaired bone marrow hematopoiesis (e.g., after cytostatic therapy) or diseases of the hematopoietic organs; hereditary deficiency of glucose-6-phosphate dehydrogenase (hemolysis); acute intermittent hepatic porphyria (risk of porphyria attacks); pregnancy (for parenteral administration – I and III trimester), breastfeeding period; childhood – various age categories depending on the dosage form and route of administration; for parenteral administration – acute renal or hepatic failure.

With caution: arterial hypotension (systolic blood pressure below 100 mm Hg), decreased blood volume, hemodynamic instability (myocardial infarction, multiple trauma, incipient shock), incipient heart failure, high fever (increased risk of sharp decrease in blood pressure). Diseases in which a significant decrease in blood pressure may be particularly dangerous (patients with severe coronary artery disease and cerebral artery stenosis). Chronic alcohol abuse. With an increased risk of developing severe anaphylactic/anaphylactoid reactions in patients with bronchial asthma, especially in combination with concomitant polypous rhinosinusitis, chronic urticaria and other types of atopy (allergic diseases, in the development of which a significant role is played by a hereditary predisposition to sensitization: hay fever, allergic rhinitis, etc.), alcohol intolerance (reaction even to small amounts of certain alcoholic beverages with symptoms such as itching, lacrimation and pronounced facial redness). For parenteral administration – II trimester of pregnancy. For oral administration – severe impairment of liver and kidney function (use of low doses is recommended due to the possibility of delayed excretion of sodium metamizole); pain of unclear etiology, especially in the abdominal area (consult a doctor before use).

Use in Pregnancy and Lactation

Contraindicated for oral administration during pregnancy. Contraindicated for parenteral administration in the I and III trimesters of pregnancy. Use with caution parenterally in the II trimester of pregnancy.

Contraindicated for use during lactation (breastfeeding).

Use in Hepatic Impairment

Contraindicated for parenteral administration in acute hepatic failure.

Should be used with caution in severe liver dysfunction (use of low doses is recommended due to the possibility of delayed excretion of sodium metamizole).

Use in Renal Impairment

Contraindicated for parenteral administration in acute renal failure.

Should be used with caution in severe renal dysfunction (use of low doses is recommended due to the possibility of delayed excretion of sodium metamizole).

Pediatric Use

Contraindicated for oral administration in children and adolescents under 15 years of age.

Contraindicated for parenteral administration in children under 3 months of age or weighing less than 5 kg.

Contraindicated for IV administration in children aged 3 to 12 months.

Geriatric Use

Should be used with caution in elderly patients. In this category of patients, the use of high doses should be avoided.

Special Precautions

When treating patients receiving cytotoxic agents, as well as children under 5 years of age, treatment with sodium metamizole should be carried out only under medical supervision.

When choosing the method of administration of sodium metamizole, it should be taken into account that parenteral administration is associated with a higher risk of anaphylactic/anaphylactoid reactions.

An increased risk of developing hypersensitivity reactions to Metamizole sodium may be due to the following conditions: analgesic bronchial asthma, especially with concomitant polypous rhinosinusitis; chronic urticaria; alcohol intolerance (hypersensitivity to alcohol), against which even when taking a small amount of certain alcoholic beverages, patients experience sneezing, lacrimation and pronounced facial redness, alcohol intolerance may indicate a previously undiagnosed aspirin asthma syndrome.

Before using sodium metamizole, a thorough patient interview should be conducted. If a risk of developing anaphylactic reactions is identified, administration is possible only after a careful assessment of the expected benefit to the possible risk of using sodium metamizole. In case of using sodium metamizole in such patients, strict medical monitoring of their condition is necessary, and means for providing emergency care in case of development of anaphylactic/anaphylactoid reactions must be available. In predisposed patients, anaphylactic shock may occur, so patients with asthma or atopy should be prescribed Metamizole sodium with caution. Patients who develop anaphylactoid reactions in response to the use of sodium metamizole are also at risk of developing them in response to the use of other non-narcotic analgesics/NSAIDs. Patients who develop anaphylactic or other immune-mediated reactions (e.g., agranulocytosis) in response to the use of sodium metamizole are also at risk of developing them in response to the use of other pyrazolones and pyrazolidines.

Life-threatening skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been described with the use of sodium metamizole. If symptoms of SJS and TEN appear, including progressive skin rash, often with blisters or mucosal involvement, treatment with sodium metamizole should be stopped immediately and should not be subsequently administered in this category of patients. Patients should be informed about the symptoms of these diseases. Skin reactions should be carefully monitored, especially during the first weeks of treatment.

With long-term use (more than 7 days), it is necessary to monitor the peripheral blood picture. Against the background of sodium metamizole intake, agranulocytosis may develop. It occurs very rarely, lasts at least a week, is not dose-dependent, can be severe, life-threatening and, in some cases, fatal. Therefore, if symptoms such as unmotivated fever, chills, sore throat, difficulty swallowing, stomatitis, erosive and ulcerative lesions of the oral cavity, vaginitis or proctitis, a decrease in the number of neutrophils in the peripheral blood below 1500/mm³ are detected, it is necessary to immediately consult a doctor and discontinue Metamizole sodium.

If pancytopenia develops, treatment should be stopped immediately, and complete blood count parameters should be monitored until they normalize.

All patients should be informed that pathological changes in the blood may be accompanied by the appearance of symptoms such as general malaise, infections, persistent fever, bruising, bleeding, pallor while taking sodium metamizole, which requires immediate medical attention.

Metamizole sodium can cause isolated hypotensive reactions. These reactions may be dose-dependent. The risk of such reactions is also increased with pre-existing arterial hypotension, decreased blood volume or dehydration, unstable hemodynamics or acute circulatory disturbance (e.g., in patients with myocardial infarction or trauma), in patients with fever. In this regard, such patients should undergo detailed diagnostics and be carefully monitored. To reduce the risk of hypotensive reactions, preventive measures (hemodynamic stabilization) may be required.

In patients in whom a decrease in blood pressure should be avoided at all costs (e.g., with severe coronary artery disease or significant cerebral artery stenosis), Metamizole sodium is allowed to be used with careful monitoring of hemodynamic parameters.

It is unacceptable to use sodium metamizole to relieve acute abdominal pain until their cause is clarified.

In patients with impaired renal or liver function, it is recommended to avoid taking sodium metamizole in high doses due to a decrease in its excretion rate. The sodium content in the product should be taken into account by persons on a low-sodium diet.

IV administration should be carried out very slowly (no more than 1 ml/min) so that at the first signs of anaphylactic/anaphylactoid reactions the administration can be stopped, as well as to minimize the occurrence of isolated hypotensive reactions.

Influence on the ability to drive vehicles and mechanisms

Given the profile of adverse reactions of sodium metamizole, caution should be exercised when driving vehicles, mechanisms, as well as when performing work that requires increased concentration and speed of psychomotor reactions.

Drug Interactions

Metamizole sodium may cause a decrease in the plasma concentration of cyclosporine, so when used simultaneously, the concentration of cyclosporine should be monitored.

With simultaneous use of sodium metamizole with chlorpromazine, the development of severe hypothermia is possible.

Simultaneous use of sodium metamizole and methotrexate or other myelotoxic agents may enhance the hematotoxicity of the latter, especially in elderly patients.

With simultaneous use, the activity of indirect anticoagulants, oral hypoglycemic drugs, corticosteroids, indomethacin is enhanced due to their displacement from binding to blood proteins under the influence of sodium metamizole.

Tricyclic antidepressants, oral contraceptives, allopurinol disrupt the metabolism of sodium metamizole in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of liver microsomal enzymes weaken the effect of sodium metamizole.

Sedatives and tranquilizers enhance the analgesic effect of sodium metamizole.

With simultaneous use of sodium metamizole, thiamazole increases the risk of developing leukopenia.

Codeine, H₂-histamine receptor blockers and propranolol enhance the effects of sodium metamizole.

When used concomitantly with acetylsalicylic acid, Metamizole sodium may reduce the effect of acetylsalicylic acid on platelet aggregation. Therefore, this combination should be used with caution when treating patients taking acetylsalicylic acid as an antiplatelet agent.

When used concomitantly, Metamizole sodium may reduce the blood concentration of bupropion.

It is known that pyrazolone derivatives can interact with indirect anticoagulants, captopril, lithium, and triamterene, and can also affect the efficacy of antihypertensive agents and diuretics.

Due to the increased risk of developing anaphylactic/anaphylactoid reactions during treatment with sodium metamizole, radiocontrast agents, colloidal blood substitutes, and penicillin should not be used.

Myelotoxic medicinal products enhance the manifestation of the hematotoxicity of sodium metamizole.

Storage Conditions

Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Analgin [Alvils, LLC (Russia)]
Solution for intravenous and intramuscular administration 1 g/2 ml: amp. 10 or 100 pcs.

Marketing Authorization Holder

Alvils, LLC (Russia)

Manufactured By

Wuhan Grand Pharmaceutical Group Co. Ltd. (China)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 1 g/2 ml: amp. 10 or 100 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml	1 amp.
Metamizole sodium	500 mg	1 g

2 ml – dark glass ampoules (10) – contour cell packaging (1) – cardboard packs.
2 ml – dark glass ampoules (10) – contour cell packaging (10) – cardboard boxes.

Analgin [Armavir Biopharmaceutical Plant, FSE (Russia)]
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 10 pcs.

Marketing Authorization Holder

Armavir Biopharmaceutical Plant, FSE (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml
Metamizole sodium	250 mg

1 ml – ampoules (10) – cardboard packs.

Analgin [Armavir Biopharmaceutical Plant, FSE (Russia)]
Solution for intravenous and intramuscular administration 500 mg/2 ml: amp. 10 pcs.

Marketing Authorization Holder

Armavir Biopharmaceutical Plant, FSE (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/2 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml	1 amp.
Metamizole sodium	250 mg	500 mg

2 ml – ampoules (10) – cardboard packs.

Analgin [Armavir Biopharmaceutical Plant, FSE (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 10 pcs.

Marketing Authorization Holder

Armavir Biopharmaceutical Plant, FSE (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml
Metamizole sodium	500 mg

1 ml – ampoules (10) – cardboard packs.

Analgin [Armavir Biopharmaceutical Plant, FSE (Russia)]
Solution for intravenous and intramuscular administration 1 g/2 ml: amp. 10 pcs.

Marketing Authorization Holder

Armavir Biopharmaceutical Plant, FSE (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 1 g/2 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml	1 amp.
Metamizole sodium	500 mg	1 g

2 ml – ampoules (10) – cardboard packs.

Analgin [Atoll LLC (Russia)]
Tablets 500 mg: from 3 to 1000 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Analgin

Tablets 500 mg: from 3 to 1000 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Metamizole sodium monohydrate	500 mg

Excipients: microcrystalline cellulose (MCC-101) – 70 mg, povidone K25 – 24 mg, magnesium stearate – 6 mg.

3 pcs. – contour cell packaging (from 1 to 100 pcs.) – cardboard packs.
4 pcs. – contour cell packaging (from 1 to 100 pcs.) – cardboard packs.
10 pcs. – contour cell packaging (from 1 to 100 pcs.) – cardboard packs.

Analgin [Atoll LLC (Russia)]
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 1 ml or 2 ml 5, 10, or 20 pcs.
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml or 2 ml 5, 10, or 20 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Forms

	Analgin	Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 1 ml or 2 ml 5, 10, or 20 pcs.
		Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml or 2 ml 5, 10, or 20 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration as a clear, colorless or slightly yellowish liquid.

	1 ml
Metamizole sodium monohydrate	250 mg

Excipients: water for injections – up to 1 ml.

1 ml – colorless glass ampoules (5) – contour cell packaging (1) – cardboard packs.
1 ml – colorless glass ampoules (5) – contour cell packaging (2) – cardboard packs.
1 ml – colorless glass ampoules (10) – contour cell packaging (1) – cardboard packs.
1 ml – colorless glass ampoules (10) – contour cell packaging (2) – cardboard packs.
2 ml – colorless glass ampoules (5) – contour cell packaging (1) – cardboard packs.
2 ml – colorless glass ampoules (5) – contour cell packaging (2) – cardboard packs.
2 ml – colorless glass ampoules (10) – contour cell packaging (1) – cardboard packs.
2 ml – colorless glass ampoules (10) – contour cell packaging (2) – cardboard packs.

Solution for intravenous and intramuscular administration as a clear, colorless or slightly yellowish liquid.

	1 ml
Metamizole sodium monohydrate	500 mg

Excipients: water for injections – up to 1 ml.

Analgin [Biosintez, PJSC (Russia)]
Tablets 500 mg: 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Metamizole sodium	500 mg

10 pcs. – non-cell contour packaging.
10 pcs. – contour cell packaging (1) – cardboard packs.

Analgin [Biosintez, PJSC (Russia)]
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml
Metamizole sodium	250 mg

1 ml – ampoules (10) – cardboard packs.

Analgin [Biosintez, PJSC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/2 ml: amp. 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/2 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml	1 amp.
Metamizole sodium	250 mg	500 mg

2 ml – ampoules (10) – cardboard packs.

Analgin [Biosintez, PJSC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml
Metamizole sodium	500 mg

1 ml – ampoules (10) – cardboard packs.

Analgin [Biosintez, PJSC (Russia)]
Solution for intravenous and intramuscular administration 1 g/2 ml: amp. 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 1 g/2 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration	1 ml	1 amp.
Metamizole sodium	500 mg	1 g

2 ml – ampoules (10) – cardboard packs.

Analgin [Biopharmkombinat, LLC (Russia)]
Tablets 500 mg: 10, 20, 30, 40, 50, 60 or 100 pcs.

Marketing Authorization Holder

Biopharmkombinat, LLC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10, 20, 30, 40, 50, 60 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Metamizole sodium	500 mg

Tablets white or white with a slightly yellowish tint, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Metamizole sodium	500 mg

Excipients: potato starch, sucrose (powdered sugar), calcium stearate, talc.

10 pcs. – contour cell packs (1) – carton packs.
10 pcs. – contour cell packs (2) – carton packs.
20 pcs. – jars (1) – carton packs.
30 pcs. – jars (1) – carton packs.

Analgin [Grotex, LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/ml: ampoules 10 pcs.

Marketing Authorization Holder

Grotex, LLC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/ml: ampoules 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration in the form of a transparent, colorless or slightly colored liquid.

	1 ml
Metamizole sodium	500 mg

Excipients: sodium hydroxide solution 0.5M – to pH 6.0 – 7.5, water for injections – up to 1 ml.

2 ml – ampoules (5) – contour cell packs (2) – carton packs.
2 ml – ampoules (10) – contour cell packs (1) – carton packs.

Analgin [Dalkhimpharm, JSC (Russia)]
Tablets 500 mg: 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Metamizole sodium	500 mg

10 pcs. – contour cell packs.
10 pcs. – contour non-cell packs.

Analgin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, slightly yellowish.

	1 ml
Metamizole sodium monohydrate	500 mg

Excipients: water for injections – up to 1 ml.

1 ml – ampoules (5) – contour cell packs (2) – carton packs.
1 ml – ampoules (10) – carton boxes.

Analgin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, slightly yellowish.

	1 ml
Metamizole sodium monohydrate	500 mg

Excipients: water for injections – up to 1 ml.

2 ml – ampoules (5) – contour cell packs (2) – carton packs.
2 ml – ampoules (10) – carton boxes.

Analgin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 1 ml 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 1 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, slightly yellowish.

	1 ml
Metamizole sodium monohydrate	250 mg

Excipients: water for injections – up to 1 ml.

1 ml – ampoules (5) – contour cell packs (2) – carton packs.
1 ml – ampoules (10) – carton boxes.

Analgin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 2 ml 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 2 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, slightly yellowish.

	1 ml
Metamizole sodium monohydrate	250 mg

Excipients: water for injections – up to 1 ml.

2 ml – ampoules (5) – contour cell packs (2) – carton packs.
2 ml – ampoules (10) – carton boxes.

Analgin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 10 ml 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 10 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, slightly yellowish.

	1 ml
Metamizole sodium monohydrate	250 mg

Excipients: water for injections – up to 1 ml.

10 ml – ampoules (5) – contour cell packs (2) – carton packs.
10 ml – ampoules (10) – carton boxes.

Analgin [Dalkhimpharm, JSC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 10 ml 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 10 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, slightly yellowish.

	1 ml
Metamizole sodium monohydrate	500 mg

Excipients: water for injections – up to 1 ml.

10 ml – ampoules (5) – contour cell packs (2) – carton packs.
10 ml – ampoules (10) – carton boxes.

Analgin [Ivanovo Pharmaceutical Factory PJSC (Russia)]
Tablets 500 mg: 10, 20, 30, 50, 100, or 200 pcs.

Marketing Authorization Holder

Ivanovo Pharmaceutical Factory PJSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10, 20, 30, 50, 100, or 200 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Metamizole sodium	500 mg

Excipients: sucrose – 10 mg, potato starch – 34 mg, talc – 1 mg, calcium stearate monohydrate (calcium stearate 1-hydrate) – 5 mg.

Weight of one tablet – 550 mg.

10 pcs. – contour cell packs (1) – carton packs.
10 pcs. – contour cell packs (2) – carton packs.
10 pcs. – contour cell packs (5) – carton packs.
10 pcs. – contour cell packs (10) – carton packs.
10 pcs. – contour cell packs (20) – carton packs.
20 pcs. – jars (1) – carton packs.
30 pcs. – jars (1) – carton packs.
10 pcs. – contour cell packs (300) – group packs (for hospitals).
10 pcs. – contour cell packs (500) – group packs (for hospitals).
10 pcs. – contour non-cell packs (300) – group packs (for hospitals).
10 pcs. – contour non-cell packs (500) – group packs (for hospitals).

Analgin [Irbit Chemical Pharmaceutical Plant, JSC (Russia)]
Tablets 500 mg: 500 or 1000 pcs.

Marketing Authorization Holder

Irbit Chemical Pharmaceutical Plant, JSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 500 or 1000 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a slightly yellowish tint, round, flat-cylindrical in shape, with a double-sided bevel and a score on one side.

	1 tab.
Metamizole sodium	500 mg

Excipients: sucrose (sugar), talc, potato starch, calcium stearate.

10 pcs. – contour non-cell packs (500) – carton boxes.
10 pcs. – contour cell packs (1000) – carton boxes.

Analgin [Marbiopharm, JSC (Russia)]
Tablets 500 mg: 10, 20 and 30 pcs.

Marketing Authorization Holder

Marbiopharm, JSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10, 20 and 30 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Metamizole sodium	500 mg

10 pcs. – contour non-cell packs.
10 pcs. – contour cell packs.
10 pcs. – contour cell packs (2) – carton packs.
10 pcs. – contour cell packs (3) – carton packs.

Analgin [Mega Pharm, CJS (Russia)]
Tablets 500 mg: 3, 4, 6, 8, 9, 10, 12, 15, 16, 18, 20, 21, 24, 27, 28, 30, 32, 36, 40, 50, 60, 70, 80, 90 or 100 pcs.

Marketing Authorization Holder

Mega Pharm, CJS (Russia)

Dosage Form

Analgin

Tablets 500 mg: 3, 4, 6, 8, 9, 10, 12, 15, 16, 18, 20, 21, 24, 27, 28, 30, 32, 36, 40, 50, 60, 70, 80, 90 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a slightly yellowish tint, round, flat-cylindrical, with a score on one side and bevels on both sides.

	1 tab.
Metamizole sodium	500 mg

Solution for intravenous and intramuscular administration transparent, colorless or slightly yellowish.

	1 ml
Metamizole sodium	0.5 g

Excipients: water for injections – up to 1 ml.

2 ml – ampoules (5) – contour cassette packs (2) – carton packs.
2 ml – ampoules (10) – carton packs.
2 ml – ampoules (10) – carton boxes.

Analgin [Organika, JSC (Russia)]
Tablets 500 mg: 10 or 20 pcs.

Marketing Authorization Holder

Organika, JSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Metamizole sodium	500 mg

10 pcs. – non-cell contour packs.
10 pcs. – contour cell packs (1) – carton packs.
10 pcs. – contour cell packs (2) – carton packs.

Analgin [Promomed Rus LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 5 or 10 pcs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Manufactured By

Biokhimik, JSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, colorless or slightly colored.

	1 ml
Metamizole sodium	500 mg

Excipients: water for injections – up to 1 ml.

2 ml – glass ampoules (5) – contour cell packs (1) – carton packs.
2 ml – glass ampoules (5) – contour cell packs (2) – carton packs.
2 ml – glass ampoules (10) – carton packs.

Analgin [Samson-Med LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 10 pcs.

Marketing Authorization Holder

Samson-Med LLC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration in the form of a transparent, colorless or yellowish liquid.

	1 ml
Metamizole sodium	500 mg

Excipients: water for injections.

2 ml – ampoules (10) – carton packs.

Analgin [Statusfarm LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 10 pcs.

Marketing Authorization Holder

Statusfarm LLC (Russia)

Manufactured By

Yerevan Chemical And Pharmaceutical Firm, OJSC (Armenia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration in the form of a transparent, colorless or yellowish liquid.

	1 ml
Metamizole sodium	500 mg

Excipients: water for injections – up to 1 ml.

2 ml – glass ampoules (10) – carton boxes.

Analgin [Tatkhimpharmpreparaty, JSC (Russia)]
Tablets 500 mg: 10 or 20 pcs.

Marketing Authorization Holder

Tatkhimpharmpreparaty, JSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Metamizole sodium	500 mg

10 pcs. – dark glass jars (1) – carton packs.
10 pcs. – non-cell contour packs.
10 pcs. – contour cell packs.
10 pcs. – contour cell packs (2) – carton packs.
10 pcs. – non-cell contour packs (2) – carton packs.

Analgin [Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)]
Tablets 500 mg: 10, 20, 30, 40, or 50 pcs.

Marketing Authorization Holder

Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Analgin

Tablets 500 mg: 10, 20, 30, 40, or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a slightly yellowish tint, flat-cylindrical in shape, with a bevel and a score.

	1 tab.
Metamizole sodium	500 mg

Excipients: sucrose – 10 mg, potato starch – 34 mg, talc – 1 mg, calcium stearate – 5 mg.

10 pcs. – contour cell packs (1) – carton packs.
10 pcs. – contour cell packs (2) – carton packs.
10 pcs. – contour cell packs (3) – carton packs.
10 pcs. – contour cell packs (4) – carton packs.
10 pcs. – contour cell packs (5) – carton packs.
10 pcs. – contour cell packs (100) – carton boxes (for hospitals).
10 pcs. – contour cell packs (200) – carton boxes (for hospitals).
10 pcs. – contour cell packs (300) – carton boxes (for hospitals).
10 pcs. – contour cell packs (400) – carton boxes (for hospitals).
10 pcs. – contour cell packs (600) – carton boxes (for hospitals).
10 pcs. – contour cell packs (800) – carton boxes (for hospitals).

Analgin [Pharmat, LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/ml: 1 ml, 2 ml, or 5 ml amp. 5, 10, 20, 50, or 100 pcs.

Marketing Authorization Holder

Pharmat, LLC (Russia)

Manufactured By

NPC Eskom, PJSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/ml: 1 ml, 2 ml, or 5 ml amp. 5, 10, 20, 50, or 100 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration in the form of a transparent, colorless or yellowish liquid.

	1 ml
Metamizole sodium monohydrate	527 mg
Equivalent to metamizole sodium content	500 mg

Solution for intravenous and intramuscular administration as a transparent, colorless or slightly yellowish liquid.

	1 ml
Metamizole sodium	500 mg

Excipients: water for injections – up to 1 ml.

2 ml – glass ampoules (5) – contour cell packaging (1) – cardboard packs.
2 ml – glass ampoules (5) – contour cell packaging (2) – cardboard packs.

Analgin [KFK Mir, LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml 3, 5, 10, or 20 pcs.

Marketing Authorization Holder

KFK Mir, LLC (Russia)

Manufactured By

NPC Eskom, PJSC (Russia)

Dosage Form

Analgin

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml 3, 5, 10, or 20 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration as a transparent, colorless or yellowish liquid.

	1 ml
Metamizole sodium monohydrate	527 mg
Equivalent to the content of metamizole sodium	500 mg

Excipients: sodium disulfite – 2 mg, disodium edetate – 0.1 mg, water for injections – up to 1 ml.

1 ml – ampoules (3) – contour cell packaging (1) – cardboard packs.
1 ml – ampoules (5) – contour cell packaging (1) – cardboard packs.
1 ml – ampoules (5) – contour cell packaging (2) – cardboard packs.
1 ml – ampoules (5) – contour cell packaging (4) – cardboard packs.
1 ml – ampoules (10) – contour cell packaging (1) – cardboard packs.
1 ml – ampoules (10) – contour cell packaging (2) – cardboard packs.
1 ml – ampoules (10) – cardboard packs with partitions.
2 ml – ampoules (3) – contour cell packaging (1) – cardboard packs.
2 ml – ampoules (5) – contour cell packaging (1) – cardboard packs.
2 ml – ampoules (5) – contour cell packaging (2) – cardboard packs.
2 ml – ampoules (5) – contour cell packaging (4) – cardboard packs.
2 ml – ampoules (10) – contour cell packaging (1) – cardboard packs.
2 ml – ampoules (10) – contour cell packaging (2) – cardboard packs.
2 ml – ampoules (10) – cardboard packs with partitions.
5 ml – ampoules (3) – contour cell packaging (1) – cardboard packs.
5 ml – ampoules (5) – contour cell packaging (1) – cardboard packs.
5 ml – ampoules (5) – contour cell packaging (2) – cardboard packs.
5 ml – ampoules (5) – contour cell packaging (4) – cardboard packs.
5 ml – ampoules (10) – contour cell packaging (1) – cardboard packs.
5 ml – ampoules (10) – contour cell packaging (2) – cardboard packs.
5 ml – ampoules (10) – cardboard packs with partitions.

Analgin [Ellara, LLC (Russia)]
Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml 5, 10, 20, or 25 pcs.
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml 5, 10, 20, or 25 pcs.

Marketing Authorization Holder

Ellara, LLC (Russia)

Dosage Forms

	Analgin	Solution for intravenous and intramuscular administration 250 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml 5, 10, 20, or 25 pcs.
		Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml 5, 10, 20, or 25 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, colorless or slightly yellowish.

	1 ml
Metamizole sodium monohydrate	250 mg

Excipients: sodium disulfite – 2 mg, disodium edetate dihydrate – 0.1 mg, sodium formaldehyde sulfoxylate dihydrate – 0.5 mg, sodium hydroxide solution 1M or sulfuric acid solution 0.5M – to pH 5.0 – 7.0, water for injections – up to 1 ml.

1 ml – light-protective glass ampoules (5) – contour cell packaging (1) – cardboard packs.
1 ml – light-protective glass ampoules (5) – contour cell packaging (2) – cardboard packs.
1 ml – light-protective glass ampoules (5) – contour cell packaging (4) – cardboard packs.
1 ml – light-protective glass ampoules (5) – contour cell packaging (5) – cardboard packs.
2 ml – light-protective glass ampoules (5) – contour cell packaging (1) – cardboard packs.
2 ml – light-protective glass ampoules (5) – contour cell packaging (2) – cardboard packs.
2 ml – light-protective glass ampoules (5) – contour cell packaging (4) – cardboard packs.
2 ml – light-protective glass ampoules (5) – contour cell packaging (5) – cardboard packs.
5 ml – light-protective glass ampoules (5) – contour cell packaging (1) – cardboard packs.
5 ml – light-protective glass ampoules (5) – contour cell packaging (2) – cardboard packs.
5 ml – light-protective glass ampoules (5) – contour cell packaging (4) – cardboard packs.
5 ml – light-protective glass ampoules (5) – contour cell packaging (5) – cardboard packs.
1 ml – light-protective glass ampoules (5) – cardboard packs with an insert.
1 ml – light-protective glass ampoules (10) – cardboard packs with an insert.
2 ml – light-protective glass ampoules (5) – cardboard packs with an insert.
2 ml – light-protective glass ampoules (10) – cardboard packs with an insert.
5 ml – light-protective glass ampoules (5) – cardboard packs with an insert.
5 ml – light-protective glass ampoules (10) – cardboard packs with an insert.

Solution for intravenous and intramuscular administration transparent, colorless or slightly yellowish.

	1 ml
Metamizole sodium monohydrate	500 mg

Analgin Alfactiv [Rif LLC (Russia)]
Tablets 500 mg

Marketing Authorization Holder

Rif LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Analgin Alfactiv

Tablets 500 mg

Dosage Form, Packaging, and Composition

Tablets

	1 tab.
Metamizole sodium	500 mg

10 pcs. – contour cell packaging – cardboard packs (10 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (10 pcs.) – cardboard packs (100 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (2 pcs.) – cardboard packs (20 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (20 pcs.) – cardboard packs (200 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (30 pcs.) – cardboard packs (300 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (4 pcs.) – cardboard packs (40 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (5 pcs.) – cardboard packs (50 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (7 pcs.) – cardboard packs (70 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (8 pcs.) – cardboard packs (80 pcs.) – Over-the-Counter
10 pcs. – contour cell packaging (9 pcs.) – cardboard packs (90 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging – cardboard packs (3 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (10 pcs.) – cardboard packs (30 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (2 pcs.) – cardboard packs (6 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (20 pcs.) – cardboard packs (60 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (3 pcs.) – cardboard packs (9 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (30 pcs.) – cardboard packs (90 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (4 pcs.) – cardboard packs (12 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (5 pcs.) – cardboard packs (15 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (6 pcs.) – cardboard packs (18 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (7 pcs.) – cardboard packs (21 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (8 pcs.) – cardboard packs (24 pcs.) – Over-the-Counter
3 pcs. – contour cell packaging (9 pcs.) – cardboard packs (27 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging – cardboard packs (4 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (10 pcs.) – cardboard packs (40 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (2 pcs.) – cardboard packs (8 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (20 pcs.) – cardboard packs (80 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (3 pcs.) – cardboard packs (12 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (30 pcs.) – cardboard packs (120 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (4 pcs.) – cardboard packs (16 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (5 pcs.) – cardboard packs (20 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (6 pcs.) – cardboard packs (24 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (7 pcs.) – cardboard packs (28 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (8 pcs.) – cardboard packs (32 pcs.) – Over-the-Counter
4 pcs. – contour cell packaging (9 pcs.) – cardboard packs (36 pcs.) – Over-the-Counter

Analgin Avexima [Avexima JSC (Russia)]
Tablets 500 mg: 10 or 20 pcs.

Marketing Authorization Holder

Avexima JSC (Russia)

Manufactured By

Avexima Siberia LLC (Russia)

Dosage Form

Analgin Avexima

Tablets 500 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a slightly yellowish tint, round, flat-cylindrical in shape, with a bevel and a score.

	1 tab.
Metamizole sodium monohydrate	500 mg

Excipients: potato starch, talc, sucrose, calcium stearate.

10 pcs. – contour non-cell packaging.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.

Analgin Avexima [Avexima JSC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml or 5 ml 5 or 10 pcs.

Marketing Authorization Holder

Avexima JSC (Russia)

Manufactured By

Avexima Siberia LLC (Russia)

Dosage Form

Analgin Avexima

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 2 ml or 5 ml 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration transparent, colorless or slightly yellowish.

	1 ml
Metamizole sodium monohydrate	527 mg,
Corresponding to the content of metamizole sodium	500 mg

Tablets

	1 tab.
Metamizole sodium	500 mg

10 pcs. – contour cell packs – cardboard packs (10 pcs.) – Over-the-Counter
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – Over-the-Counter
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – Over-the-Counter
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – Over-the-Counter
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – Over-the-Counter

Analgin Renewal [Obnovlenie Pfc, JSC (Russia)]
Tablets 500 mg: 10 or 20 pcs.

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Analgin Renewal

Tablets 500 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a bevel, with a score on one side and an engraving “R” on the other.

	1 tab.
Metamizole sodium	500 mg

Excipients: povidone K30, potato starch, talc, calcium stearate, stearic acid, colloidal silicon dioxide (aerosil).

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.

Analgin Renewal [PFKO-2, LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/ml

Marketing Authorization Holder

PFKO-2, LLC (Russia)

Manufactured By

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Analgin Renewal

Solution for intravenous and intramuscular administration 500 mg/ml

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration

	1 ml
Metamizole sodium	500 mg

1 ml – ampoules (10 pcs.) – cardboard packs – By prescription
1 ml – ampoules (20 pcs.) – cardboard boxes – for hospitals
1 ml – ampoules (25 pcs.) – cardboard boxes – for hospitals
1 ml – ampoules (250 pcs.) – cardboard boxes – for hospitals
1 ml – ampoules (5 pcs.) – cardboard packs – By prescription
1 ml – ampoules (50 pcs.) – cardboard boxes – for hospitals
1 ml – ampoules (500 pcs.) – cardboard boxes – for hospitals
2 ml – ampoules (10 pcs.) – cardboard packs – By prescription
2 ml – ampoules (20 pcs.) – cardboard boxes – for hospitals
2 ml – ampoules (25 pcs.) – cardboard boxes – for hospitals
2 ml – ampoules (250 pcs.) – cardboard boxes – for hospitals
2 ml – ampoules (5 pcs.) – cardboard packs – By prescription
2 ml – ampoules (50 pcs.) – cardboard boxes – for hospitals
2 ml – ampoules (500 pcs.) – cardboard boxes – for hospitals
5 ml – ampoules (10 pcs.) – cardboard packs – By prescription
5 ml – ampoules (20 pcs.) – cardboard boxes – for hospitals
5 ml – ampoules (25 pcs.) – cardboard boxes – for hospitals
5 ml – ampoules (250 pcs.) – cardboard boxes – for hospitals
5 ml – ampoules (5 pcs.) – cardboard packs – By prescription
5 ml – ampoules (50 pcs.) – cardboard boxes – for hospitals
5 ml – ampoules (500 pcs.) – cardboard boxes – for hospitals

Analgin tablets 0,5 [As-Pharm OJSC (Russia)]
Tablets 500 mg: 10 or 20 pcs.

Marketing Authorization Holder

As-Pharm OJSC (Russia)

Dosage Form

Analgin tablets 0,5

Tablets 500 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Metamizole sodium	500 mg

Tablets	1 tab.
Metamizole sodium	500 mg

Tablets

Metamizole sodium

500 mg

10 pcs. – jars – cardboard packs (10 pcs.) – Over-the-Counter
10 pcs. – blister contour packs – cardboard packs (10 pcs.) – Over-the-Counter
10 pcs. – blister contour packs (2 pcs.) – cardboard packs (20 pcs.) – Over-the-Counter
10 pcs. – blister contour packs (3 pcs.) – cardboard packs (30 pcs.) – Over-the-Counter
10 pcs. – blister contour packs (4 pcs.) – cardboard packs (40 pcs.) – Over-the-Counter
10 pcs. – blister contour packs (5 pcs.) – cardboard packs (50 pcs.) – Over-the-Counter
10 pcs. – blister contour packs (6 pcs.) – cardboard packs (60 pcs.) – Over-the-Counter
20 pcs. – jars – cardboard packs (20 pcs.) – Over-the-Counter
30 pcs. – jars – cardboard packs (30 pcs.) – Over-the-Counter
40 pcs. – jars – cardboard packs (40 pcs.) – Over-the-Counter
50 pcs. – jars – cardboard packs (50 pcs.) – Over-the-Counter
60 pcs. – jars – cardboard packs (60 pcs.) – Over-the-Counter

Analgin Velpharm [Elzapharm, LLC (Russia)]
Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml

Marketing Authorization Holder

Elzapharm, LLC (Russia)

Manufactured By

Velpharm, LLC (Russia)

Dosage Form

Analgin Velpharm

Solution for intravenous and intramuscular administration 500 mg/1 ml: amp. 1 ml, 2 ml, or 5 ml

Dosage Form, Packaging, and Composition

Solution for intravenous and intramuscular administration as a transparent, colorless or slightly colored liquid.

	1 ml
Metamizole sodium monohydrate	500 mg

Excipients : 1M hydrochloric acid solution, water for injection.

1 ml – ampoules (10 pcs.) – cardboard packs – By prescription
1 ml – ampoules (100 pcs.) – cardboard container – for hospitals
1 ml – ampoules (240 pcs.) – cardboard container – for hospitals
1 ml – ampoules (250 pcs.) – cardboard container – for hospitals
1 ml – ampoules (480 pcs.) – cardboard container – for hospitals
1 ml – ampoules (5 pcs.) – cardboard packs – By prescription
1 ml – ampoules (500 pcs.) – cardboard container – for hospitals
2 ml – ampoules (10 pcs.) – cardboard packs – By prescription
2 ml – ampoules (100 pcs.) – cardboard container – for hospitals
2 ml – ampoules (240 pcs.) – cardboard container – for hospitals
2 ml – ampoules (250 pcs.) – cardboard container – for hospitals
2 ml – ampoules (480 pcs.) – cardboard container – for hospitals
2 ml – ampoules (5 pcs.) – cardboard packs – By prescription
2 ml – ampoules (500 pcs.) – cardboard container – for hospitals
3 ml – ampoules (10 pcs.) – cardboard packs – By prescription
3 ml – ampoules (5 pcs.) – cardboard packs – By prescription
5 ml – ampoules (100 pcs.) – cardboard container – for hospitals
5 ml – ampoules (240 pcs.) – cardboard container – for hospitals
5 ml – ampoules (250 pcs.) – cardboard container – for hospitals
5 ml – ampoules (480 pcs.) – cardboard container – for hospitals
5 ml – ampoules (500 pcs.) – cardboard container – for hospitals

Analgin-ExtraCap [Pharmstandard-Lexredstva OJSC (Russia)]
Capsules 500 mg: 10, 20 or 50 pcs.

Marketing Authorization Holder

Pharmstandard-Lexredstva OJSC (Russia)

Dosage Form

Analgin-ExtraCap

Capsules 500 mg: 10, 20 or 50 pcs.

Dosage Form, Packaging, and Composition

Capsules hard gelatin No. 00, white; capsule contents – white or white with a yellowish tint powder. The presence of a compacted capsule mass is allowed, which easily crumbles when pressed with a glass rod.

	1 caps.
Metamizole sodium	500 mg

Excipients : potato starch – 15.32 mg, calcium stearate – 4.68 mg.

Capsule shell composition (body and cap) titanium dioxide (E 171) – 2%, gelatin up to 100%

10 pcs. – blister contour packs (1) – cardboard packs.
10 pcs. – blister contour packs (2) – cardboard packs.
10 pcs. – blister contour packs (5) – cardboard packs.

Analgin-LecT [Tyumen Chemical and Pharmaceutical Plant, JSC (Russia)]
Tablets 500 mg: 10, 20, 30, 40, 50, or 60 pcs.

Marketing Authorization Holder

Tyumen Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Analgin-LecT

Tablets 500 mg: 10, 20, 30, 40, 50, or 60 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a slight yellowish tint, round, flat-cylindrical in shape, with a bevel and a score line.

	1 tab.
Metamizole sodium (calculated as monohydrate)	500 mg

Excipients : potato starch – 31.1 mg, talc – 10.7 mg, calcium stearate – 5.4 mg, sucrose (sugar) – 2.8 mg.

10 pcs. – non-cell contour packs (1) – cardboard packs.
10 pcs. – non-cell contour packs (2) – cardboard packs.
10 pcs. – non-cell contour packs (3) – cardboard packs.
10 pcs. – blister contour packs (1) – cardboard packs.
10 pcs. – blister contour packs (2) – cardboard packs.
10 pcs. – blister contour packs (3) – cardboard packs.
10 pcs. – blister contour packs (4) – cardboard packs.
10 pcs. – blister contour packs (5) – cardboard packs.
10 pcs. – blister contour packs (6) – cardboard packs.

Analgin-UBF [Uralbiopharm, JSC (Russia)]
Tablets 500 mg: 10, 20, 30, 40, 50 and 60 pcs.

Marketing Authorization Holder

Uralbiopharm, JSC (Russia)

Dosage Form

Analgin-UBF

Tablets 500 mg: 10, 20, 30, 40, 50 and 60 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Metamizole sodium	500 mg

10 pcs. – non-cell contour packs.
10 pcs. – blister contour packs.
20 pcs. – polymer jars.
30 pcs. – polymer jars.
40 pcs. – polymer jars.
50 pcs. – polymer jars.
60 pcs. – polymer jars.

Analgin-Ultra [Aliym, JSC (Russia)]
Film-coated tablets, 500 mg: from 5 to 420 pcs.

Marketing Authorization Holder

Aliym, JSC (Russia)

Dosage Form

Analgin-Ultra

Film-coated tablets, 500 mg: from 5 to 420 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets pink, biconvex, oblong in shape with rounded ends, with a score line; on the cross-section the core is white or almost white.

	1 tab.
Metamizole sodium	500 mg

Excipients : potato starch, microcrystalline cellulose, colloidal silicon dioxide (aerosil), hypromellose (hydroxypropyl methylcellulose), crospovidone, magnesium stearate, talc.

Shell composition Opadry II 85F34555 pink [polyvinyl alcohol, titanium dioxide, macrogol, talc, aluminum lake based on brilliant red dye, aluminum lake based on sunset yellow dye, aluminum lake based on azorubine dye].

From 5 to 30 pcs. – blister contour packs (from 1 to 14 pcs.) – cardboard packs.

Analgin-Ultra [FP Obolenskoe, JSC (Russia)]
Film-coated tablets, 500 mg: 5, 10 or 20 pcs.

Marketing Authorization Holder

FP Obolenskoe, JSC (Russia)

Manufactured By

Kirov Pharmaceutical Company, LLC (Russia)

PharmVILAR NPO, LLC (Russia)

Dosage Form

Analgin-Ultra

Film-coated tablets, 500 mg: 5, 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets pink, biconvex, oblong in shape with rounded ends, with a score line; on the cross-section the core is white or almost white.

	1 tab.
Metamizole sodium	500 mg

Excipients : potato starch, microcrystalline cellulose, colloidal silicon dioxide (aerosil), hypromellose (hydroxypropyl methylcellulose), crospovidone, magnesium stearate, talc.

Shell composition opadry II 85F34555 pink [polyvinyl alcohol, titanium dioxide, macrogol, talc, aluminum lake based on brilliant red dye, aluminum lake based on sunset yellow dye, aluminum lake based on azorubine dye].

5 pcs. – blister contour packs (1) – cardboard packs.
10 pcs. – blister contour packs (1) – cardboard packs.
20 pcs. – blister contour packs (1) – cardboard packs.

Medixlife (Author)

View all posts Profile link